Ignite Creation Date:
2024-05-05 @ 10:01 PM
Last Modification Date:
2024-10-26 @ 10:12 AM
Study NCT ID:
NCT01014637
Status:
UNKNOWN
Last Update Posted:
2009-11-17
First Post:
2009-11-16
Brief Title:
Efficacy Safety and Cost-effectiveness of a Sequential Therapy With RV4104A Ointment Ciclopiroxolamine Cream and Ciclopirox Film-forming Solution Compared With Amorolfine Nail Lacquer in Dermatophytic Onychomycosis
Sponsor:
Pierre Fabre Dermo Cosmetique
Organization:
Pierre Fabre Dermo Cosmetique
Study Overview
Official Title:
A Multicentre Randomized Controlled Study of the Efficacy Safety and Cost-effectiveness of a Sequential Therapy With RV4104A Ointment Ciclopiroxolamine Cream and Ciclopirox Film-forming Solution Compared With Amorolfine Nail Lacquer Alone for the Treatment of Dermatophytic Onychomycosis Toenail Without Matrix Involvement
Status:
UNKNOWN
Status Verified Date:
2009-11
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ONICO
Brief Summary:
The purpose of the study is to evaluate and compare the efficacy of the sequential association RV4104A ointment followed by ciclopiroxolamine 1 cream and ciclopirox 8 film-forming solution versus amorolfine 5 nail lacquer alone in the treatment of patients with dermatophytic onychomycosis toenail without matrix involvement
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None